Dipeptidyl peptidase‐4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study
Authors:
Open Access
- 9 April 2019
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (8) , 1719-1727
Abstract
Aims: To evaluate the real‐world effect of dipeptidyl peptidase‐4 inhibitor (DPP4i) on the incidence of autoimmune diseases (AD), including rheumatoid arthritis (RA), inflammatory bowel diseases, multiple sclerosis and systemic lupus erythematosus.Methods: We identified new users of DPP4i (n = 497 619) or non‐DPP4i (n = 643 165) oral combination therapy between 1 January 2011 and 30 June 2015 among patients with type 2 diabetes mellitus in the Korean national health insurance claims database. Patients were followed from the date of initiation of combination therapy until AD outcome, censoring for treatment discontinuation or switching, death or end of study (31 August 2016). Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) for RA, inflammatory bowel diseases, other AD (multiple sclerosis and systemic lupus erythematosus), and the composite of all outcomes were estimated using propensity score (PS)‐adjusted Cox model.Results: In the PS‐weighted and PS‐matched analysis, the risk of incident RA was decreased for DPP4i initiators compared with non‐DPP4i initiators (aHR 0.67 [95% CI 0.49–0.92] and aHR 0.72 [95% CI 0.51–1.01], respectively). In both analyses, the risk of incident composite AD was also decreased for DPP4i initiators compared with non‐DPP4i initiators (aHR 0.82 [95% CI 0.68–0.99] and aHR 0.76 [95% CI 0.62–0.93], respectively).Conclusions: In this large population‐based cohort study, upfront DPP4i combination therapy was associated with a lower risk of composite AD compared with initial non‐DPP4i combination therapy.Keywords
Funding Information
- Ewha Womans University (RP‐Grant 2016)
This publication has 37 references indexed in Scilit:
- Differentiating among incretin therapies: a multiple-target approach to type 2 diabetesJournal of Clinical Pharmacy and Therapeutics, 2012
- Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?Trends in Pharmacological Sciences, 2009
- Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular riskNutrition, Metabolism and Cardiovascular Diseases, 2008
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell functionTrends in Immunology, 2008
- Insights into different results from different causal contrasts in the presence of effect-measure modificationPharmacoepidemiology and Drug Safety, 2006
- Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform EffectAmerican Journal of Epidemiology, 2005
- Marginal Structural Models as a Tool for StandardizationEpidemiology, 2003
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Dipeptidyl Peptidase IV (DP IV, CD26) in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 2001